PR-Inside.com logo PR-Inside.com 1 month ago

Biogen Idec to Present at the 2009 Annual Credit Suisse Healthcare Conference

Refer to a friend 2009-11-09 23:40:04 - days following the presentation. About Biogen Idec Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Full Article at PR-Inside.com

Related Topics:

  1. NCI, Inc.
  2. Alnylam Pharmaceuticals, Inc.
  3. Hawkins, Inc.

Related Articles

  1. PR-Inside.com logo
    ImmunoGen, Inc. Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ..
    1 month ago

    2009-11-10 12:38:04 - Daniel Junius, President and Chief Executive Officer. “We’ll be reporting updated clinical data with our IMGN901 compound when used for the treatment of CD56-expressing solid tumors. Full Article at PR-Inside.com

  2. PR-Inside.com logo
    Alnylam to Webcast R&D Day on Thursday, November 12, 2009
    1 month ago

    2009-11-09 15:54:03 - two guest speakers. Full Article at PR-Inside.com

  3. PharmaTimes logo
    'Benign' label change for Elan/Biogen’s Tysabri
    1 month ago

    09 November 2009 Elan Corp and partner Biogen Idec have made changes to the label on Tysabri to reflect the increased risk of a rare and potentially fatal brain disease when the multiple sclerosis blockbuster is taken over a... Full Article at PharmaTimes

  4. Biogen 3Q Profit Beats Views On Smaller Charges
    1 month ago

    CAMBRIDGE, Mass. -- Biogen Idec Inc. said Tuesday its profit jumped 34 percent in the third quarter due to lower amortization costs and increased sales of its multiple sclerosis drug Tysabri. Full Article at Boston Channel.com

Related Quotes

  1. rFIXFc is an example of Biogen Idec's commitment to developing innovative therapies to address significant unmet medical needs. The rFIXFc program has the potential to improve the lives of individuals with hemophilia B and we are excited about advancing the program
    SOURCE: Medical News Today 1 month ago
  2. The Phase I/II results are very encouraging. The decision to initiate our first registrational program represents true progress in our efforts to offer hemophilia B patients treatment that makes a significant difference and is also an important milestone in the ongoing development of Biovitrum
    SOURCE: Medical News Today 1 month ago
(What's this?)
  1. Are you a Publisher?

    We built Daylife.com using our SmartMedia Services platform, which can give you thousands of content-rich, advertiser-friendly pages (like this one) on any topic and with full editorial control. Learn More »

    Our Customers
    prev
    next
  2. Our Products
    Daylife Select

    A point & click tool to create dynamic content portals. Learn More »

  3. Daylife API

    Unlimited smart, customizable content to suit any publisher. Learn More »

  4. Enterprise API

    Use the Daylife Platform to distribute content across your sites. Learn More »

  5. SmartContext

    Weave the web's best content into your own. Learn More »

Browse More Photos

Daylife is the web's largest archive of news photos

  1. FILE - In this Oct. 11, 2007 file photo, activist investor Carl Icahn speaks at the World Business Forum in New York.
  2. FILE - In this file product image provided by Abbott Laboratories, the North Chicago-based company's rheumatoid arthritis therapy Humira, is shown.

Cast of Characters

  1. Genentech, Inc. Genentech, Inc.
  2. NCI, Inc.
  3. NASDAQ NASDAQ
  4. Alnylam Pharmaceuticals, Inc.
  5. See stories, photos, and quotes about Hawkins, Inc. Hawkins, Inc.
  6. Loews Loews